Indian Counterpart Asks U.S. HHS To Intervene In Ranbaxy Dispute
This article was originally published in PharmAsia News
Executive SummaryIndia's health ministry, acting on behalf of Ranbaxy Laboratories, is asking its U.S. counterpart to intervene in a dispute with U.S. FDA over allegations Ranbaxy imported adulterated drugs into the country. The head of India's Chemicals and Fertiliser Ministry made the appeal in a letter to Michael Leavitt, secretary of Health and Human Services. Ram Vilas Paswan asked Leavitt to "have the matter resolved at the earliest." Paswan agreed with Ranbaxy that it had not been involved in wrongdoing and that the firm has cooperated with U.S. authorities so it can get an amicable resolution of the dispute. (Click here for more
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.